RxDoctor Payments Data

Laura Young, APRN

Psychiatric/Mental Health · Overland Park, KSNPI 1689349243

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,750 of the $5,098 with a category attached, or 73.6%. AbbVie accounts for 86.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $4,333, more than ten times the $25 reported in 2022.

$5,098in general payments, 2019–2025

Across 67 payments — averaging $76.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Alkermes, Inc.$166
  • H2-pharma, LLC$150
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$134
  • Otsuka America Pharmaceutical, Inc.$100
  • Johnson & Johnson$77
  • plus $68 from 4 others

What the payments were for

  • Speaking & faculty fees$3,75074%
  • Food & beverage$1,34826%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,098 in reported general payments places this provider in the 85th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$39,302
Medicare patients
86
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$25,785
Vilazodone Hcl28$3,288
Quetiapine Fumarate ErQuetiapine Fumarate25$1,929
Lurasidone Hcl17$743
Duloxetine Hcl18$738
Naltrexone Hcl13$617
Bupropion XlBupropion Hcl31$587
Gabapentin12$523
Aripiprazole21$515
Trazodone Hcl46$459
Quetiapine Fumarate37$456
Lamotrigine37$356
Prazosin Hcl20$349
Clonazepam39$313
Methylphenidate Hcl13$265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$4,403$25,78516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →